Welcome to our dedicated page for BCHTD SEC filings (Ticker: BCHTD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BCHTD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BCHTD's regulatory disclosures and financial reporting.
Birchtech Corp. expanded its recent stock sale through a partial use of the underwriters’ over-allotment option. The company originally sold 6,250,000 common shares at $2.40 per share, generating gross proceeds of $15.0 million.
On March 17, 2026, the underwriters bought an additional 600,000 shares at the same price, adding approximately $1.4 million of gross proceeds. In total, 6,850,000 shares have been issued in the offering, with aggregate gross proceeds of about $16.4 million and 337,500 over-allotment shares still available.
Birchtech Corp. completed an underwritten public offering of 6,250,000 shares of common stock at $2.40 per share, generating approximately $13.1 million in net proceeds. Underwriters also have a 30‑day option to buy up to 937,500 additional shares, which would lift net proceeds to about $15.2 million if fully exercised.
The company plans to use the cash, together with existing funds, for ongoing operating expenses, working capital and other general corporate purposes. Birchtech’s CEO purchased $750,000 of stock in the deal, or 312,500 shares, and directors and executive officers agreed to a 90‑day lock‑up. The offering supports Birchtech’s uplisting, as its common stock was approved for trading on the NYSE American under the symbol BCHT while remaining listed on the Toronto Stock Exchange.
Birchtech Corp. plans a primary offering of 4,464,286 shares of common stock, with an assumed price of $3.36 per share, and has granted underwriters a 30‑day option for 669,643 additional shares. Estimated net proceeds are about $13.1 million, or $15.2 million if the option is fully exercised.
The company provides specialty activated carbon technologies for mercury emissions control at coal‑fired power plants and is expanding into PFAS-focused water treatment. As of February 11, 2026, 19,455,966 shares were outstanding, rising to 23,920,252 after the offering. Key risks include heavy reliance on evolving U.S. environmental regulations, customer concentration, active patent challenges, going‑concern uncertainty, and dependence on collection of a $78.4 million patent judgment that is under appeal.
Birchtech Corp. is conducting a primary offering of 5,449,592 shares of common stock, based on an assumed public offering price of $3.67 per share. The company expects to raise approximately $17.7 million in net proceeds, or about $20.5 million if underwriters fully exercise a 817,439‑share over‑allotment option.
Shares outstanding are expected to increase from 19,455,966 to 24,905,558. Birchtech plans to use the cash, together with existing funds, for ongoing operating expenses, working capital, and general corporate purposes. The company has applied to list its stock on the NYSE American under the symbol “BCHT”, with NYSE American approval a condition to closing the deal; trading would cease on the OTCQB if the uplisting occurs.
Birchtech provides specialty activated carbon technologies for mercury emissions control at coal‑fired power plants and is expanding into water treatment focused on PFAS removal. It highlights regulatory uncertainty around U.S. emissions and water rules, customer concentration, patent protection challenges, and a going concern risk given a year‑end 2025 cash balance of about $2.3 million.